Trajan Scientific and Medical (Trajan) Chief Executive Officer Stephen Tomisich, delivered the opening plenary at AusMedtech 2016 in Adelaide from 10 - 11 May, discussing how to grow and sustain scientific and medical device companies.
Mr Tomisich's address covered three key pillars to Trajan's business sustainability; foundation, activity, and risk mitigation.
View the full plenary video below, or on Trajan's YouTube channel.
Media contact information
Tel: +44 (0) 1244 403 100
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.